Innovation Pharmaceuticals Inc (IPIX)

[olden_grumpini]

Thanks for pointing this out.

The point I was trying to make about Aspire is that they couldn't time the market the way this new purchaser can. Although Aspire had shares at their disposal they had no way of knowing when IPIX would issue a purchase request. IPIX controlled the timing of that request. That's a big difference imo.

So what happened in 2018? I took a look at the period from when the deal was announced to the end of the year 2018. I also looked at the PRs that IPIX issued during the same time period (list is below).

On the day the deal was announced, IPIX opened at $0.24. At the end of 2018 IPIX closed at $0.10 (they opened that day at $0.08). The PRs that IPIX issued during the time period suggested that positive things were happening on multiple fronts. Also, IPIX was a more robust organization with core staffing in place in 2018.

If you think the timeframe is too short, the share price closed on October 7, 2019 (1 year out) at $0.11. The decline in share price was most likely the result of dilution imo.

October 09, 2018
INNOVATION PHARMACEUTICALS SECURES UP TO $10 MILLION IN ADDITIONAL FINANCING TO ADVANCE CLINICAL PIPELINE

October 12, 2018
INNOVATION PHARMACEUTICALS BRILACIDIN AS A NOVEL INHIBITOR OF PHOSPHODIESTERASE 4 (PDE4) SUPPORTS ITS POTENTIAL TO TREAT AUTOIMMUNE AND INFLAMMATORY DISEASES

October 22, 2018
INNOVATION PHARMACEUTICALS PROVIDES UPDATE ON KEVETRIN PROGRAM; BRIDGING TOXICOLOGY EFFORTS AIMED AT DEVELOPING AN ORAL P53 ANTI-CANCER DRUG CANDIDATE

October 24, 2018
INNOVATION PHARMACEUTICALS GRANTED END-OF-PHASE 2 MEETING

November 01, 2018
INNOVATION PHARMACEUTICALS EXPANDS BRILACIDIN PATENT PORTFOLIO

November 08, 2018
INNOVATION PHARMACEUTICALS PROVIDES CORPORATE UPDATE HIGHLIGHTING BUSINESS DEVELOPMENT AND CLINICAL PIPELINE PRIORITIES

November 13, 2018
INNOVATION PHARMACEUTICALS PRESENTING BRILACIDIN FOR INFLAMMATORY BOWEL DISEASE AT “IBD INNOVATE 2018” CONFERENCE HOSTED BY THE CROHN’S & COLITIS FOUNDATION

December 17, 2018
INNOVATION PHARMACEUTICALS COMPLETES END-OF-PHASE 2 MEETING WITH FDA; BRILACIDIN ORAL RINSE TO ADVANCE INTO PHASE 3 CLINICAL TRIALS FOR PREVENTION OF SEVERE ORAL MUCOSITIS